Market News AIOpen the app

Erasca and Bristol Myers Squibb are teaming up to test a new cancer treatment for pancreatic cancer.

DealRead the original at pluang.com
Neutral

Bristol Myers Squibb will sponsor an early test of navlimetostat with Erasca's drug. No patient results or payment terms were reported, so the trial does not yet show a change to BMS's outlook.

BMY · Bristol Myers Squibb

AI read · Neutral

The AI's read

The study is still at an early testing stage, so it has not shown that the drug combination helps patients. BMS will sponsor the trial, but the report gives no cost or payment details. No patient results or financial change are reported to support a different business outlook yet.

ERAS · Erasca, Inc.

AI read · Neutral

The connection

Erasca will supply its drug for an early test with BMS's treatment. No patient results or payment terms were reported, so this does not yet show a change to Erasca's outlook.

Get alerts for BMY

Follow Bristol Myers Squibb (BMY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BMY
Free on the App Store and Google Play, or on the web.